2015
DOI: 10.1016/s0016-5085(15)31431-1
|View full text |Cite
|
Sign up to set email alerts
|

Su1160 A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of 7 Days of Orally Administered Nepadutant in Infants With Colic - the NO-CRY Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2015
2015
2016
2016

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…In this study the drug exposure (PK assessment) was also assessed to provide additional information on the dose‐effect relationship, thus supporting the dose selection and dosing schedule in the future studies . Preliminary results of the first study demonstrate that nepadutant at the high dose (0.5 mg/kg) is effective and safe in treating infantile colic . The outcomes of the second study are currently not yet available.…”
Section: Tk Receptors As Targets For Treatments Of Functional Gi Disomentioning
confidence: 99%
See 1 more Smart Citation
“…In this study the drug exposure (PK assessment) was also assessed to provide additional information on the dose‐effect relationship, thus supporting the dose selection and dosing schedule in the future studies . Preliminary results of the first study demonstrate that nepadutant at the high dose (0.5 mg/kg) is effective and safe in treating infantile colic . The outcomes of the second study are currently not yet available.…”
Section: Tk Receptors As Targets For Treatments Of Functional Gi Disomentioning
confidence: 99%
“…110 Preliminary results of the first study demonstrate that nepadutant at the high dose (0.5 mg/kg) is effective and safe in treating infantile colic. 111 The outcomes of the second study are currently not yet available.…”
Section: Antagonists Of Nk2 Receptorsmentioning
confidence: 99%
“…However, it should be noted that in the overall IBS population studied, Ibodutant ® was not superior to placebo. In infants with colic, an abstract has reported that Nepadutant ® (MEN-11420), a neurokinin 2 antagonist, had efficacy in a phase II, randomized, double blind, placebo-controlled trial [ 21 ]. Though infants with colic may go on to manifest childhood FGIDs [ 22 ], there are currently no studies using neurokinin 2 antagonists in childhood IBS.…”
Section: Introductionmentioning
confidence: 99%